StockData

Azitra vs Alaunos Therapeutics

AZTR and TCRT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AZTR and TCRT compare

Azitra is the larger company, worth 8.7 times as much as Alaunos Therapeutics ($36.8M against $4.2M).

Alaunos Therapeutics scores higher on the StockData Score (4 against 1 for Azitra), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAZTRTCRT
Size and price
Market cap$36.8M$4.2M
Share price$0.608$1.66
Change, 1 year67.0%−44.1%
Change, 5 years–−99.2%
Beta (5Y)–−2.45
Employees131
StockData Score
Total score14 (better)
Valuation score00
Growth score00
Performance score00
Health score14 (better)
Dividend score00
Valuation
P/S–1406×
P/B5.0× (better)6.5×
FCF yield−30.3%–
Growth
Revenue growth (TTM)–−50.0%
Profitability
Operating margin–−135267%
Net margin–−133667%
Return on equity−257%−186% (better)
Return on invested capital−1090%−489% (better)
Financial health
Debt / equity–0.00
Interest coverage−1164.7×–
Current ratio4.86 (better)0.77
Altman Z-score−1.70 (better)−861.74
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield−14.8%–
Shareholder yield−14.8%0.00% (better)
Ownership
Held by institutions35.7%3.6%
Held by insiders9.6%69.8%
Short interest, % of float0.56%24.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.